News
-
October 01, 2020- Healthcare professional and patient campaigns focus on screening for early-stage T1D-
Provention Bio, Inc. (Nasdaq:PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, yesterday launched a national effort to redefine patient care in type 1...
-
September 30, 2020- Expect to complete filing of the rolling Biologics License Application (BLA) submission for teplizumab in Q4 2020 -
Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the submission of the clinical module of the...
-
September 08, 2020
Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will present at three upcoming...
-
August 31, 2020Potential to be the first approved therapeutic for the treatment of Non-responsive Celiac Disease
Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the initiation of the Phase 2b PROACTIVE...
-
August 11, 2020-Former Director of the Office of New Drugs at the FDA's Center for Drug Evaluation and Research, brings extensive regulatory expertise and experience to Provention-
Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the appointment of John K. Jenkins, MD to the...
-
August 06, 2020- Completed commercial-scale drug substance PPQ campaign ahead of schedule, enabling the expected on-time completion of the rolling Biologics License Application (BLA) submission for teplizumab in Q4 2020 -
Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial results for the second...
-
August 03, 2020
Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the appointment of Heidy Abreu King-Jones to the...
-
July 30, 2020
Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its second...
-
June 30, 2020
Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today a change in the format of its 2020 Annual...
-
June 29, 2020
Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it has been added to the broad-market...
-
June 22, 2020
Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today the closing of the previously announced public...
-
June 17, 2020
Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the pricing of its previously announced...
-
June 16, 2020
Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it has commenced an underwritten public...
-
June 15, 2020-One Course of Teplizumab Now Shown to Delay Insulin-Dependent T1D by a Median of Approximately Three Years Compared to Placebo-
Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced extended follow-up data showing a single 14-day...
-
May 28, 2020
Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that management will present at the Jefferies...
-
May 20, 2020- Nancy Wysenski, a Seasoned Pharmaceutical Executive with Rare Disease and Commercialization Experience, Appointed as a New Director -
Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced two changes to its board of...
-
May 18, 2020-- The preclinical prototype vaccine is well-tolerated and provides strong protection against coxsackievirus B infections and diabetes in relevant animal models
Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease and its licensor, Vactech Oy (Vactech), a Finnish...
-
May 07, 2020- Company on Track to Complete Submission of Rolling Biologics License Application for Teplizumab in Q4 2020 -
Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported financial results and provided a...
-
April 30, 2020
Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it will report its first...
-
April 16, 2020- Rolling BLA Submission Initiated Under Breakthrough Therapy Designation
Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the initiation of the rolling...
-
March 16, 2020- PROTECT Study Randomization to be Paused Temporarily in Response to the Ongoing Public Health Crisis
Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced a temporary pause in the...
-
March 12, 2020- Expect to Complete Submission of a BLA for PRV-031 (Teplizumab) in Q4 2020
Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported financial results for the fourth...
-
March 12, 2020-PRV-3279 Inhibited the Function of B Cells, Durably and Without Depletion-
Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced positive top-line results from...
-
March 05, 2020
Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its fourth...
-
February 19, 2020
Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that management will present at...
-
February 06, 2020JDRF T1D Fund Study Estimates 2.3 Million People at Risk Globally to Develop Stage 3 T1D, Which Already Affects 18 Million People Globally
Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today highlighted several new research studies on...
-
January 08, 2020
Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the appointment of Jason Hoitt as...
-
December 12, 2019Expects to Complete Submission of a BLA for PRV-031 (Teplizumab) in Q4 2020
Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it completed a Type B...
-
November 05, 2019- PRV-031 (teplizumab) Granted Breakthrough Therapy and PRIME Designations -
Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported financial results for the third...
-
October 29, 2019
Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its third...
-
October 24, 2019
Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the European Medicines Agency...
-
October 22, 2019-Study Did Not Achieve Primary Endpoint Due to High Placebo Effect-
Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced top-line results from its...
-
September 26, 2019- T1D Fund Executive Chairman and Former Bain Capital Managing Director Brings Extensive Financial Expertise and Deep Knowledge of Therapeutics Landscape -
Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the appointment of Sean Doherty...
-
September 25, 2019
Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that management will present at...
-
September 24, 2019- FDA Meeting Expected in Q4 2019 and BLA Submission for PRV-031 (teplizumab) Targeted for Q4 2020 -
Provention Bio, Inc., (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reiterated its regulatory strategy...
-
September 18, 2019
Provention Bio, Inc., (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the pricing of its previously...
-
September 18, 2019
Provention Bio, Inc., (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it has commenced an...
-
September 05, 2019
Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that management will present at...
-
August 20, 2019- Appoints Dr. Sherron Kell as SVP of Clinical Development and Program Lead for PRV-031 (Teplizumab) -
Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the appointment of Sherron Kell,...
-
August 08, 2019-Bispecific Diabody Designed to Intercept B-Cell Mediated Autoimmune Diseases-
Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it has dosed the first...
-
August 06, 2019PRV-031 Granted Breakthrough Therapy Designation for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals
Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported financial results for the second...
-
August 05, 2019
Provention Bio, Inc. (Nasdaq:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that the U.S. Food and Drug...
-
June 13, 2019
Provention Bio, Inc. (Nasdaq: PRVB) announced today that it has terminated the public offering of common stock previously announced on June 10, 2019. The termination results from an assessment by...
-
June 10, 2019
Provention Bio, Inc. (Nasdaq: PRVB) announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a registered...
-
June 09, 2019Results from the NIH-Sponsored "At-Risk" Study Published in The New England Journal of Medicine and Presented at the American Diabetes Association Annual Meeting
Provention Bio, Inc. (Nasdaq:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that results from the National...
-
May 08, 2019PROTECT Pivotal Phase 3 Clinical Study Initiated in Patients with Recent Onset Type 1 Diabetes
Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported financial results for the first...
-
May 08, 2019
Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced preliminary top-line results from...
-
April 24, 2019- Top-line Data Anticipated in the Fourth Quarter of 2019 -
Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it has completed the...
-
April 09, 2019Pivotal Study to Evaluate Potential of Anti-CD3 Monoclonal Antibody to Intercept Type 1 Diabetes
Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it has dosed the first...
-
April 02, 2019Strengthens Leadership Team with Appointment of Douglas Jacobstein, M.D. as V.P. of Clinical Development and Alex Rabiee as V.P. of Business Development
Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the appointment of Douglas...
-
March 28, 2019Dr. Bluestone is a World-renowned Expert and Academic Leader in Immune Tolerance Research
Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the appointment of Jeffrey...
-
March 19, 2019Plan to Initiate PROTECT Study for PRV-031 (teplizumab) in T1D Patients in Q2
Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported financial results for the fourth...
-
March 12, 2019
Provention Bio, Inc. (Nasdaq:PRVB), a clinical-stage biopharmaceutical company focused on preventing and intercepting immune-mediated diseases, announced today it will host a conference call and...
-
February 13, 2019
Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics aimed at intercepting and preventing immune-mediated diseases, announced...
-
January 28, 2019Provention is currently developing PRV-101 as a polyvalent vaccine for acute coxsackie virus infection and to potentially prevent the onset of T1D
Provention Bio, Inc. (Nasdaq:PRVB), a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics aimed at intercepting and preventing immune-mediated diseases, announced...
-
January 03, 2019Provention is currently developing PRV-101 as a vaccine for acute coxsackie infection and to potentially prevent the onset of T1D
Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics aimed at intercepting and preventing immune-mediated diseases, announced...
-
November 28, 2018
Provention Bio, Inc. (Nasdaq:PRVB), a clinical-stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing...
-
November 08, 2018Conference Call and Live Audio Webcast Scheduled for Today at 8:30 a.m., ET
Q3 2018 and Recent Corporate Highlights: Completed $63.9 million upsized initial public offering Announced co-development agreement with Amgen and in-licensing of PRV-015 (Amgen's AMG-714), a...
-
November 05, 2018Provention to Lead Phase 2b Stage of Development for Anti-IL-15 Antibody AMG 714
THOUSAND OAKS, Calif. and OLDWICK, N.J. – (Nov. 5, 2018) – Amgen (NASDAQ:AMGN) and Provention Bio, Inc. (NASDAQ:PRVB), a clinical-stage biopharmaceutical company focused on immune-mediated...
-
November 01, 2018
Provention Bio, Inc. (Nasdaq:PRVB), a clinical-stage biopharmaceutical company focused on preventing and intercepting immune-mediated diseases, announced today it will host a conference call and...
-
October 23, 2018- Top-line data from the "PULSE" clinical trial expected in the second quarter of 2019
Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company focused on immune-mediated diseases, announced today that it has completed enrollment in the Phase 1b clinical trial...
-
September 11, 2018
Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today its Chief Executive Officer...
-
September 05, 2018Industry executive adds considerable financial expertise as audit committee chairperson
Provention Bio, Inc. (Nasdaq:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today the appointment of Avery (Chip) W....
-
August 13, 2018
Recent Corporate Highlights: Closed initial public offering of common stock on July 19, 2018, generating $63.9 million in gross proceeds Expanded pipeline with two additional clinical-stage assets...
-
July 31, 2018- Provention strengthens its strategic platform in type 1 diabetes (T1D) interception and prevention
Provention Bio, Inc. (Nasdaq:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today the appointment of Mark Rigby, MD,...
-
July 19, 2018
Provention Bio, Inc. (Nasdaq:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today the closing of its initial public...
-
May 09, 2018-- Provention acquires PRV-031 (teplizumab) and plans to initiate pivotal Phase 3 clinical trial to intercept early-onset type 1 diabetes, a pediatric orphan indication
Provention Bio, Inc., a clinical-stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing immune-mediated...
-
May 07, 2018- Coxsackievirus B appears to be an important trigger for type 1 diabetes
Provention Bio, Inc. (Provention), a clinical stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing...
-
September 28, 2017-- Andrew Drechsler Named Chief Financial Officer
Provention Bio, Inc., a clinical-stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing immune-mediated...
-
September 21, 2017- Provention to initiate Phase 2a Study of PRV-6527 (JNJ-40346527) in patients with moderate to severe Crohn's disease
Provention Bio, Inc., a clinical stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing immune-mediated...
-
July 18, 2017- Enterovirus vaccine platform in-licensed from Vactech Oy will be developed to "pre-empt" type 1 diabetes by targeting coxsackievirus B infection
Provention Bio, Inc., a clinical stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing immune-mediated...
-
July 11, 2017Accomplished Biopharmaceutical and Drug Development Executive to Spearhead Provention's Vision of Intercepting and Preventing Immune-mediated Disease
Provention Bio, Inc., a clinical-stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing immune-mediated...
-
June 26, 2017Industry innovators, Francisco Leon, MD, Ph.D. and Ashleigh Palmer, cofound newly established company
Provention Bio, Inc., a recently founded clinical-stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing...